Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
about
Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FNew Therapeutic Approaches in Polycythemia VeraMonitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging ApproachesStem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry.Efficacy of ruxolitinib for myelofibrosis.Experience with ruxolitinib in the treatment of polycythaemia vera.p53 at the crossroads of MPN treatment.DNMT3A in haematological malignancies.Current and future treatment options for polycythemia vera.Mechanisms of thrombogenesis in polycythemia veraThe orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary RoundtableMolecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Novel and emerging therapies for the treatment of polycythemia veraDiagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.Ruxolitinib for the treatment of patients with polycythemia vera.Advances and challenges in the management of essential thrombocythemia.Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials.DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.Can pegylated interferon improve the outcome of polycythemia vera patients?Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
P2860
Q26766319-AE5E60C7-98A2-4E27-9783-D3F343853547Q26779929-C2C60300-6B5E-4A9F-A569-DAE8CA737A73Q26795666-5EE4C2BF-F16D-4798-A477-FA18B9D92971Q26795677-3C1A36E3-53F2-43C3-81FD-126D3FCC9564Q28076096-BF555A17-696C-410D-962F-AC7B7CB22C33Q31156217-FAAE9E6F-11F0-45BC-8BBE-274C31A03429Q33415489-B5620923-219C-44CD-9387-9E4217F91400Q33605624-4B264265-8F8E-4398-8FC4-CAEDADFB5D24Q33987032-C2CA66A1-6CC2-4854-8E9A-32EBA2B5BFA6Q34463554-768ED0D8-A2E6-43A2-8448-A88445325ED2Q35572748-F0890F3D-2916-46F5-BAC6-D89488003E80Q35738656-3765180F-3F4F-4BA1-B61B-86A9E49E35B9Q35743852-DC8A62A8-EDF6-45BE-8D18-3A580DEC6056Q35987564-9A5B93FE-A266-46BF-B7AC-0ABEFFDB1A07Q36169641-330A0497-A2BA-4AFA-B719-A7F22AD1463AQ36169783-6C857CBF-A43A-4FD9-84C9-5C2662AD341BQ36266377-477EC48B-5FD1-40EC-837B-5E07B0224DBEQ36311347-8D04BA10-7071-4A22-92E2-A318E699FF4BQ36782943-C5B50AC0-6CE6-41E8-88EC-CFDA6D52BF91Q37069633-3D0E0850-BF93-4995-AED4-DAE6A4B8B27DQ37679175-001894A5-186B-434D-BF12-DE241028C628Q38187684-C0F6305A-869B-4E97-AC28-16FA234C0A9CQ38255717-5FEDFDDD-A182-4EA9-97AD-06333D4441E4Q38484321-E9AEE62E-C298-440F-BA8A-4BEEDB4D3658Q38542093-EB4A4462-DBFD-4C5F-BE0A-081EEF91DF5AQ38646051-8B4C93EF-F3DF-46C9-A456-3B10809D6FAEQ38740700-82D3C68D-4825-47F3-8E25-856E849EFE5DQ38742500-2681C42C-108B-4D36-9D47-B590F14CB207Q38774457-9B5AEC12-9C4D-4615-99C4-4B4DDF3A3658Q38909050-B85E3113-988D-4188-ADEF-B26B5E1E25B4Q39306368-C9A5FD35-30CA-443A-8E74-C0EA68EABC4DQ39453577-107FB535-21C1-4533-B9A1-DA7707883C9EQ39979643-9301F95A-0EB9-4E9C-A058-F06FF6A16DDBQ40858775-A904265E-B102-46B6-A2EB-3897E2213C32Q40959669-E9483398-B586-4CC5-8D2D-639E2FCA4E63Q42062133-93F20010-EEA9-4C66-B619-1ED789CB1D7FQ42330314-74853DC1-1FF4-4C05-A7FC-B48AE6ADC3D6Q42609605-1F2E196E-83E5-484B-845F-4E87E5D6A6FCQ44993985-450A17BB-447A-4E7B-BCAF-802FEFF6434FQ46525156-046C93F9-0F89-4BEE-8AA9-1E0C392104B8
P2860
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular analysis of patients ...... ving pegylated interferon α-2a
@en
Molecular analysis of patients ...... ing pegylated interferon α-2a.
@nl
type
label
Molecular analysis of patients ...... ving pegylated interferon α-2a
@en
Molecular analysis of patients ...... ing pegylated interferon α-2a.
@nl
prefLabel
Molecular analysis of patients ...... ving pegylated interferon α-2a
@en
Molecular analysis of patients ...... ing pegylated interferon α-2a.
@nl
P2093
P2860
P50
P1433
P1476
Molecular analysis of patients ...... ving pegylated interferon α-2a
@en
P2093
Alfonso Quintás-Cardama
Anne-Laure Roupie
David Harris
Omar Abdel-Wahab
Outi Kilpivaara
Ross L Levine
Su-Jiang Zhang
Taghi Manshouri
P2860
P304
P356
10.1182/BLOOD-2012-07-442012
P407
P577
2013-06-19T00:00:00Z